You can buy or sell TNXP and other stocks, options, ETFs, and crypto commission-free!
Tonix Pharmaceuticals Holding Corp. Common Stock, also called Tonix Pharmaceuticals, is a clinical-stage biopharmaceutical company, which engages in discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Read More It focuses on delivering a safe and effective long-term treatment for posttraumatic stress disorder. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Seeking AlphaMay 23
Tonix up 9% premarket on new pipeline candidate
Tonix Pharmaceuticals (NASDAQ:TNXP) has in-licensed a Phase 2 asset, TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) for the treatment of cocaine intoxication.
Seeking AlphaMay 22
Tonix perks up 17% as capital raise looms
Nano cap Tonix Pharmaceuticals (TNXP +17% ) is up on below-average volume. Shares have jumped 30% since Monday but remain mired in a pronounced downtrend that began in July of last year after lead drug Tonmya (cyclobenzaprine HCl sublingual tablets) failed a late-stage study in posttraumatic stress disorder. The stock has lost over 90% of its value since then. No particular news accounts for the recent action, although the company will soon need to execute a capital raise. In its most recent 10-Q, it state...
Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA
NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors, effective May 6, 2019. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, "We are pleased to welcome Dr. Goodman to the Tonix Board, as he brings 20 years of biopharmaceutical research and development leadership experience that will be invaluable to Tonix as we grow the company. We have benefitted from ...
-$1.08 per share
-$1.29 per share